搜索肿瘤医学资讯

编者按：2020年ASCO会议已落下帷幕，但追寻更好的治疗策略的脚步却从未停止。我国胃癌年新发病例约50万，占全球新发病例的一半，是名副其实的胃癌大国。随着近年精准治疗的发展，胃癌的HER2检测和围术期抗HER2治疗不断开拓。今年ASCO会议中，PETRARCA研究的FLOT+PH双靶围术期方案显著提高pCR率，虽然该研究止步于此，但给PH双靶围术期治疗HER2阳性胃癌带来了无限遐想。因此，肿瘤瞭望特邀天津医科大学肿瘤医院梁寒教授和北京大学肿瘤医院张小田教授从PETRARCA研究出发，对话HER2阳性胃癌围术期的治疗现状、进展与挑战。

Editor’s note: The annual meeting of American Society of Clinical Oncology (ASCO) was held in the form of online conference for the first time， the theme of ASCO 2020 is “Unite and ConDr Liuer: Accelerating Progress Together”. In this ASCO meeting， Latest researh advances in all fields of cancer have been publised and presented， in the aspect of CAR-T treatment， Oral abstract of 8001(ALEXANDER study) became the focus of ASCO， dual-targeting CAR-T (AUTO3) shows significant efficacy and safety in relapsed and refractory Diffuse Large B Cell Lymphoma (r/r-DLBCL). In order to learn more about ALEXANDER study and other related Dr Liuestions about CAR-T， we invited Dr Zhiming Li who is from Sun Yat-sen University Cancer Center as the host of this interview， and first author of ALEXANDER study Dr Osborne made a deep analysis of ALEXANDER study and dual-targeting CAR-T therapy.

At the 2020 ASCO conference， Professor Thomas Powles from Barts Cancer Institute and the London School of Medicine and Dentistry， UK， has reported the JAVELIN Bladder 100 study， which showed that patients with advanced urothelial cancer treated with avilumab as the first-line maintenance therapy followed with chemotherapy could significantly improve OS compared with the control group. In this interview， Professor Yu Wei from the first hospital of Peking University will talk to Professor Powles to share the main results of this study and the immunotherapy strategy for advanced urothelial cancer.

Editor’s note: May 29th， 2020 to 2nd June 2020， the annual meeting of the American Society of Clinical Oncology (ASCO) was held as a virtual meeting online and many important advances were presented at this ASCO. ASCO annual meeting is the largest international academic meeting in the field of cancer. ENDURANCE study is a phase 3 trial that compared triplet regimen of KRd with VRd for the treatment of newly diagnosed multiple myeloma (NDMM). In order to learn more about this study， we invited Professor Hou Jian from Department of Hematology， Renji Hospital Affiliated to Shanghai Jiao tong University， and Professor Shaji Kumar from Hematology Department of Mayo Clinic (first author of ENDURANCE study); the two experts made a comprehensive analysis of ENDURANCE study and MM therapy.

编者按：美国临床肿瘤学会（ASCO）年会已经落下帷幕，虽然受新冠疫情影响，ASCO首次以线上会议形式召开，但精彩程度及重磅研究可谓毫不逊色。外周T细胞淋巴瘤（PTCL）一直是治疗上的难点及挑战，本次ASCO上，一项来自我国郑州大学第一附属医院的临床研究（大会摘要号：8018）提出了PTCL一线治疗的新思路，研究显示GDPT方案（吉西他滨/顺铂/强的松/沙利度胺）在治疗缓解率和生存方面均优于经典的CHOP方案（环磷酰胺/多柔比星/长春新碱/泼尼松）。为了深入理解该研究，《肿瘤瞭望》特邀采访了南开大学天津人民医院肿瘤内科王华庆教授，对该研究及PTCL的治疗进行了点评。

神经内分泌瘤（NENs）是一类少见的肿瘤类型。在每年的ASCO年会上都只有极少部分有关这个肿瘤诊治的内容，但每年的ASCO上也都会有一些比较值得留意的摘要发表，激发我们在这一小众肿瘤领域不断探索前进。《肿瘤瞭望》杂志特邀中山大学附属第一医院陈洁教授为大家带来精彩解读，一窥这一领域最新研究进展。

编者按：2020年6月11日~21日，第25届欧洲血液学年会（EHA）首次以线上形式召开。作为欧洲血液学领域规模最大的国际性会议，每年都有来自全球100多个国家的10000余名专业人士与会，一起分享并探讨有关血液学的创新理念及最新的科学和临床研究成果。造血干细胞移植是目前治愈重度地中海贫血的重要手段，移植理念与技术不断进步。本次EHA大会高博医学（血液病）研究中心南方春富（儿童）血液病研究院廖建云主任分享了逐渐减停免疫抑制剂与供者淋巴细胞输注治疗重型地中海贫血移植后排斥的疗效比较。

受全球新冠肺炎疫情影响，2020年美国临床肿瘤学会年会（ASCO）于5月29日~31日首次以线上形式举办，但精彩程度却不遑多让。在急性髓细胞白血病（AML）领域也涌现了多项重要研究，其中摘要7509/7510/7511尤为值得关注，为了更好地掌握今年ASCO会议上AML研究进展，《肿瘤瞭望》特邀采访了中国医学科学院血液病医院的王建祥教授，全面解读了以上三项重磅研究，现整理如下，以供读者参考。

编者按：2020年6月11日~21日，第25届欧洲血液学年会（EHA）首次以线上形式召开。作为欧洲血液学领域规模最大的国际性会议，每年都有来自全球100多个国家的10000余名专业人士与会，一起分享并探讨有关血液学的创新理念及最新的科学和临床研究成果。造血干细胞移植是目前治愈重度地中海贫血的重要手段，移植理念与技术不断进步。本次EHA大会高博医学（血液病）研究中心南方春富（儿童）血液病研究院廖建云主任分享了供者淋巴细胞输注促进重型地中海贫血新鲜脐血移植植入率的临床研究。

COVID-19全球疫情阻断不了医学科学前进的步伐。